

Company Overview

Orgenesis is a vertically-integrated biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. The Company's MaSTherCell subsidiary is a global Contract Development and Manufacturing Organization (CDMO). Through MaSTherCell, Orgenesis is able to deliver optimized process industrialization capacities to cell therapy companies, and speed up the arrival of these therapies onto the market. MaSTherCell's customers include many of the world's leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy. Orgenesis is also developing its own propriety cell therapies. Through its subsidiary Orgenesis Ltd., Orgenesis is a pioneer in the process of Transdifferentiation (or cell reprogramming), whereby an adult cell is converted into another type of cell, with its distinct phenotype and function. Orgenesis has utilized its proprietary technology/processes to successfully reprogram human liver cells into glucose-responsive, fully functional, insulin producing cells. Converting the diabetic patient's own tissue into insulin-producing cells has the potential to provide a practical cure for insulin dependent diabetes and overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation.

Orgenesis CEO Appears as a Guest on i24 News Network

Nov 13 2019, 7:00 AM EST

Stock Overview

Symbol	ORGS
Exchange	Nasdaq
Market Cap	52.69m
Last Price	\$3.26
52-Week Range	\$2.77 - \$6.32

11/20/2019 04:00 PM EST

Investor Relations

Crescendo Communications, LLC
David K. Waldman
T: (212) 671-1020
orgs@crescendo-ir.com

Management Team

Vered Caplan

President, Chief Executive Officer and Director

Neil Reithinger, CPA

Chief Financial Officer, Secretary, and Treasurer

Sarah Ferber Ph.D.

Chief Scientific Officer

Orgenesis Inc.

Germantown Innovation Center
20271 Goldenrod Lane
Germantown, MD 20876

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.